|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:nucleotide
|
|
gptkbp:administeredBy
|
other direct-acting antivirals
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AX15
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:brand
|
gptkb:Sovaldi
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:category
|
gptkb:antiviral_drug
gptkb:prodrug
nucleotide analog inhibitor
|
|
gptkbp:chemicalFormula
|
prodrug of a nucleotide analog
|
|
gptkbp:combines
|
gptkb:daclatasvir
ribavirin
ledipasvir
velpatasvir
|
|
gptkbp:contraindication
|
severe bradycardia with amiodarone
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:discoveredBy
|
gptkb:Michael_Sofia
|
|
gptkbp:drugClass
|
gptkb:direct-acting_antiviral
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericAvailable
|
yes (in some countries)
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:indication
|
all HCV genotypes (in combination)
chronic hepatitis C infection
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
gptkb:NS5B_polymerase_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:priceRange
|
high (notably expensive in US and Europe)
|
|
gptkbp:resistantTo
|
rare, but possible with NS5B mutations
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
headache
insomnia
|
|
gptkbp:target
|
gptkb:HCV_NS5B_polymerase
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:DB08912
gptkb:Antiviral
gptkb:PSI-7977
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sofosbuvir
|